Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Drug re-purposing specialist Nuformix posted a first-half loss as its revenue fell.
Pre-tax losses for the six months through September amounted to £0.48 million, compared to losses of £0.13 million year-on-year.
Revenue dropped to £0.20 million, down from £0.54 million.
Nuformix said it was continuing discussions with potential partners on licensing its lead asset, NXP002, for the Asian market.
At 9:28am: (LON:NFX) Nuformix Plc share price was 0p at 2.95p